These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Peritogiannis V; Tsouli S J Clin Psychiatry; 2011 Jul; 72(7):1016; author reply 1016-7. PubMed ID: 21824463 [No Abstract] [Full Text] [Related]
47. Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel. Warawa EJ; Migler BM; Ohnmacht CJ; Needles AL; Gatos GC; McLaren FM; Nelson CL; Kirkland KM J Med Chem; 2001 Feb; 44(3):372-89. PubMed ID: 11462978 [TBL] [Abstract][Full Text] [Related]
48. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Waddington JL; Cross AJ; Gamble SJ; Bourne RC Science; 1983 Apr; 220(4596):530-2. PubMed ID: 6132447 [TBL] [Abstract][Full Text] [Related]
50. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Gerlach J; Casey DE Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):103-12. PubMed ID: 1967845 [TBL] [Abstract][Full Text] [Related]
51. An update on tardive dyskinesia. Simpson GM; Pi EH; Sramek JJ Hosp Community Psychiatry; 1986 Apr; 37(4):362-9. PubMed ID: 2870977 [TBL] [Abstract][Full Text] [Related]
52. The dopamine D1 receptor: biochemical and behavioral aspects. Andersen PH; Nielsen EB Adv Exp Med Biol; 1986; 204():73-91. PubMed ID: 2878580 [No Abstract] [Full Text] [Related]
53. A pharmacological and theoretical comparison of high and low potency neuroleptics. Zavodnick S J Clin Psychiatry; 1978 Apr; 39(4):332-6. PubMed ID: 24619 [TBL] [Abstract][Full Text] [Related]
54. The possible role of dopamine autoreceptors in neuroleptic atypicality. Javitt DC; Weinstein SL; Opler LA Psychiatr Dev; 1988; 6(1):57-71. PubMed ID: 2902622 [TBL] [Abstract][Full Text] [Related]
55. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Clow A; Jenner P; Marsden CD Eur J Pharmacol; 1979 Aug; 57(4):365-75. PubMed ID: 39769 [TBL] [Abstract][Full Text] [Related]
56. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002 [TBL] [Abstract][Full Text] [Related]
57. Drug therapy of tardive dyskinesia. Kobayashi RM N Engl J Med; 1977 Feb; 296(5):257-60. PubMed ID: 12469 [No Abstract] [Full Text] [Related]
58. Is there a limbic system equivalent of tardive dyskinesia? Davis KL; Rosenberg GS Biol Psychiatry; 1979 Aug; 14(4):699-703. PubMed ID: 39641 [TBL] [Abstract][Full Text] [Related]
59. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Chouinard G; Jones BD Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522 [TBL] [Abstract][Full Text] [Related]